Carregant...
FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome
Myelodysplastic syndrome (MDS) is a heterogeneous myeloid malignancy characterized by blood cell morphological dysplasia, ineffective clonal hematopoiesis, and risk of transformation to secondary acute myeloid leukemia (sAML). A number of genetic abnormalities have been identified in MDS and sAML, b...
Guardat en:
| Publicat a: | Blood Cancer J |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group UK
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7538974/ https://ncbi.nlm.nih.gov/pubmed/33024076 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-020-00362-7 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|